BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: DeVita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, Michelis MF. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 2003;60:335-40. [PMID: 14640239 DOI: 10.5414/cnp60335] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Petzer V, Tymoszuk P, Asshoff M, Carvalho J, Papworth J, Deantonio C, Bayliss L, Wake MS, Seifert M, Brigo N, Valente de Souza L, Hilbe R, Grubwieser P, Demetz E, Dichtl S, Volani C, Berger S, Böhm F, Hoffmann A, Pfeifhofer-Obermair C, von Raffay L, Sopper S, Arndt S, Bosserhoff A, Kautz L, Perrier P, Nairz M, Wolf D, Weiss G, Germaschewski V, Theurl I. A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease. Blood 2020;136:1080-90. [PMID: 32438400 DOI: 10.1182/blood.2019004653] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
2 Kuo KL, Hung SC, Wei YH, Tarng DC. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 2008;19:1817-26. [PMID: 18495964 DOI: 10.1681/ASN.2007101084] [Cited by in Crossref: 65] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
3 Joshi AD, Holdford DA, Brophy DF, Harpe SE, Mays D, Gehr TW. Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study. Anemia 2012;2012:248430. [PMID: 22577528 DOI: 10.1155/2012/248430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
4 Macdougall IC. Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions. Clin Kidney J 2017;10:i16-24. [PMID: 29225819 DOI: 10.1093/ckj/sfx043] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
5 . Chapter 2: Use of iron to treat anemia in CKD. Kidney Int Suppl (2011) 2012;2:292-8. [PMID: 25018949 DOI: 10.1038/kisup.2012.34] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
6 Schneider A, Schneider MP, Scharnagl H, Jardine AG, Wanner C, Drechsler C. Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes. BMC Nephrol 2013;14:67. [PMID: 23521816 DOI: 10.1186/1471-2369-14-67] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
7 Roger SD, Tio M, Park HC, Choong HL, Goh B, Cushway TR, Stevens V, Macdougall IC. Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis. Nephrology (Carlton) 2017;22:969-76. [PMID: 27699922 DOI: 10.1111/nep.12940] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
8 Robinson BM, Larkina M, Bieber B, Kleophas W, Li Y, Locatelli F, McCullough KP, Nolen JG, Port FK, Pisoni RL. Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). BMC Nephrol 2017;18:330. [PMID: 29121874 DOI: 10.1186/s12882-017-0745-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
9 Hatamizadeh P, Ravel V, Lukowsky LR, Molnar MZ, Moradi H, Harley K, Pahl M, Kovesdy CP, Kalantar-Zadeh K. Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant 2013;28:2889-98. [PMID: 24169614 DOI: 10.1093/ndt/gft411] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
10 Chuengsaman P, Narenpitak S, Sritippayawan S. Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis. World J Nephrol 2021; 10(6): 109-121 [PMID: 34909408 DOI: 10.5527/wjn.v10.i6.109] [Reference Citation Analysis]
11 O'Lone EL, Hodson EM, Nistor I, Bolignano D, Webster AC, Craig JC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2019;2:CD007857. [PMID: 30790278 DOI: 10.1002/14651858.CD007857.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
12 Toblli JE, Di Gennaro F. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. PLoS One 2015;10:e0125528. [PMID: 25928811 DOI: 10.1371/journal.pone.0125528] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
13 Elstrott B, Khan L, Olson S, Raghunathan V, DeLoughery T, Shatzel JJ. The role of iron repletion in adult iron deficiency anemia and other diseases. Eur J Haematol 2020;104:153-61. [PMID: 31715055 DOI: 10.1111/ejh.13345] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
14 Khalil SK, Amer HA, El Behairy AM, Warda M. Oxidative stress during erythropoietin hyporesponsiveness anemia at end stage renal disease: Molecular and biochemical studies. J Adv Res 2016;7:348-58. [PMID: 27222740 DOI: 10.1016/j.jare.2016.02.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
15 Kapoian T, O’Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19:372-379. [PMID: 18216316 DOI: 10.1681/asn.2007050606] [Cited by in Crossref: 128] [Cited by in F6Publishing: 43] [Article Influence: 9.1] [Reference Citation Analysis]
16 Miskulin DC, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer KB, Ephraim PL, Michels WM, Jaar BG, Crews DC, Scialla JJ, Sozio SM, Shafi T, Wu AW, Cook C, Boulware LE; Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Network Patient Outcomes in End Stage Renal Disease Study Investigators. Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 2014;9:1930-9. [PMID: 25318751 DOI: 10.2215/CJN.03370414] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
17 Sun CC, Vaja V, Chen S, Theurl I, Stepanek A, Brown DE, Cappellini MD, Weiss G, Hong CC, Lin HY, Babitt JL. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant 2013;28:1733-43. [PMID: 23345622 DOI: 10.1093/ndt/gfs584] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
18 Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011;26:1599-607. [PMID: 20929915 DOI: 10.1093/ndt/gfq613] [Cited by in Crossref: 114] [Cited by in F6Publishing: 105] [Article Influence: 9.5] [Reference Citation Analysis]